United CEO Martine Rothblatt

With pipeline set­backs mount­ing, Unit­ed snares pri­or­i­ty vouch­er for in­haled for­mu­la­tion of PAH med Ty­va­so

De­spite a big lead in pul­monary ar­te­r­i­al hypterten­sion, Unit­ed Ther­a­peu­tics is un­der the gun as it looks to stave off com­peti­tors and build a suc­cess­ful …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.